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Acute pancreatitis (AP) is an inflammatory disease in
which the regulatory pathways are not clearly eluci-
dated. Activation of interleukin 1 (IL-1) and immuno-
modulation via MyD88, the first signaling molecule in
the ST2 pathway, seem to be involved. Because IL-33, the
ST2 ligand, is an IL-1 family member and acts as an
alarmin, we explored the ST2 pathway in human and
mouse AP. Soluble ST2 was assayed by enzyme-linked
immunosorbent assay (ELISA) in plasma of 44 patients
admitted for AP. The levels of soluble ST2 increased
early during AP and correlated with parameters of se-
verity. Under two different experimental models of AP
(ie, choline-deficient-ethionine-supplemented diet and
cerulein injections), ST2-deficient mice (Il1rl1/) pre-
sented with more severe disease than wild-type mice,
with increased activation of mast cells. In vitro,
Il1rl1/ bone-marrow-derived mast cells exhibited ex-
acerbated degranulation, compared with the wild type.
Flow cytometry identified mast cells as the main perito-
neal population expressing ST2. Using immunohisto-
chemistry and ELISA, we showed constitutive expres-
sion of IL-33 in murine pancreas and its release during
experimental AP. Correlated with AP severity, increased
soluble ST2 levels evoke involvement of the ST2 path-
way in human AP. Furthermore, our experimental data
suggest a protective role for ST2 during AP, highlighting
the potential regulatory role of mast cells and the pos-
sibility of the ST2 pathway as a new therapeutic target in
2330AP. (Am J Pathol 2012, 180:2330–2339; http://dx.doi.org/
10.1016/j.ajpath.2012.03.009)
Acute pancreatitis (AP) is an inflammatory disease
characterized by an overall mortality rate of 5%, which
reaches 17% for necrotizing pancreatitis.1 At present,
no specific medical therapy targeting the inflammatory
storm of AP has a proven clinical benefit.2 A better
understanding of the regulatory inflammatory pathways
in AP is mandatory for discovery of new therapeutic
targets.
The initial phase of AP involves disruption of acinar
cells and pancreatic autodigestion, followed by activation
of local inflammatory cells and release of proinflammatory
cytokines, among which the interleukin-1 (IL-1) system,
activated early during AP, was shown to play a pivotal
role in promoting local tissue destruction and extra-
pancreatic organ failure.3 Indeed, blockade of the IL-1
receptor (IL-1R) is able to attenuate the propagation of
pancreatic injury and associated inflammation in murine
models.4,5 A newly identified member of the IL-1 family,
IL-33 [also known as interleukin-1 family member 11 (IL-
1F11)] is characterized by a dual function. IL-33 can
either regulate gene transcription in the nucleus, damp-
ening proinflammatory signaling,6,7 or be released as an
alarmin by cells undergoing necrosis, triggering inflam-
mation in an autocrine or paracrine manner.8,9 IL-33 sig-
nals through a receptor complex by binding to the ST2
receptor10 and recruiting the coreceptor IL-1R accessory
protein (IL-1R AcP).11 The ST2 receptor belongs to the
family of Toll-like/IL-1 receptor (TIR) domain receptors
and is expressed on Th2 lymphocytes, mast cells, and
some epithelial cells.12 The ST2 gene (IL1RL1) encodes
Supported by the Belgian National Fund for Scientific Research (FNRS).
R.O. is an FNRS research fellow, A.L. is an FNRS postdoctoral researcher,
and D.D. is an FNRS M.D. and Ph.D. student. A grant from E. Jacobs
contributed to the project.
Accepted for publication March 1, 2012.
Address reprint requests to Arnaud Lemmers, M.D., Ph.D., Erasme
Hospital, Department of Gastroenterology, Hepatopancreatology, and Di-
gestive Oncology. Université Libre de Bruxelles (ULB). Route de Lennik,
808, 1070 Brussels, Belgium. E-mail: arnaud.lemmers@erasme.ulb.ac.be.
Involvement of ST2 in Acute Pancreatitis 2331
AJP June 2012, Vol. 180, No. 6two isoforms of ST2 proteins: ST2L, a transmembrane
form, and soluble ST2 (sST2), a secreted form that can
serve as a decoy receptor by binding IL-33 and thus
inhibiting its signaling through ST2L.13 Along with pro-
moting a Th2 response, ST2 has been shown to seques-
ter MyD88, the first signaling molecule activated by TLR4
and IL-1R1. This effect has identified ST2 as a key reg-
ulator in endotoxin tolerance.14
Given that the IL-1 cytokine family is activated early in
the course of AP, that speculation exists concerning se-
cretion of alarmins during AP necrosis, and that MyD88
might regulate the AP inflammatory storm, we investi-
gated whether the IL-33-ST2 pathway might be involved
in AP in humans and in mice.
Materials and Methods
Patients
Plasma from 44 patients admitted to our institution for an
episode of AP between 2005 and 2008 was studied.
Inclusion criteria were, first, the taking of the blood sam-
ple less than 24 hours after onset of symptoms, and then
at least two of the following: typical pain, amylase and
lipase concentrations at least thrice the upper normal
limit, and compatible modifications observed under im-
aging. Clinical characteristics of these patients are given
in Table 1.
The etiologies of AP were biliary for 61% of the pa-
tients, alcoholic for 21%, and miscellaneous (including
hypertriglyceridemia, unknown or familial etiology, and
intraductal papillary mucinous tumor) for 18%. Patients
with chronic pancreatitis were excluded. Necrotizing
pancreatitis was defined by the absence of enhancement
of pancreatic tissue on contrast-injected computed to-
mography or magnetic resonance imaging.15 Severe AP
was defined using the Atlanta classification,16 involving
the presence of one of the following at any time during the
AP course: i) failure of one or more organ systems (re-
spiratory, renal, gastrointestinal, circulatory), dissemi-
nated intravascular coagulation, or hypocalcemia 7.5
mg/dL; ii) occurrence of one or more local complications
(pancreatic necrosis, pseudocyst, or abscess); or iii) a
score of 3 on Ranson’s criteria or a score of 8 on the
Acute Physiology and Chronic Health Evaluation II scor-
ing system (APACHE II).2 Blood samples were taken on
the day of admission and were repeated 1, 2, 7, and 30
days later. Sixteen healthy volunteers with no history of
pancreatic disease were recruited and served as control.
Plasma was stored at 20°C until the assay. The study
was performed after approval of the Erasmus Hospital
ethics committee. Written informed consent was obtained
from each participant (see NCT01315613 at http://www.
clinicaltrials.gov).
Mouse Models of Acute Pancreatitis
Wild-type (WT) and ST2-deficient (Il1rl1/) mice17 back-
crossed with the BALB/c strain for six generations were
housed in conventional facilities. For the first AP model,
after overnight fasting, 6-week-old female mice were feda choline-deficient ethionine-supplemented (CDE) diet
(MP Biomedicals, Solon, OH) for 72 hours. For the sec-
ond pancreatitis model, female mice were injected hourly
with 50 g/kg cerulein i.p. (Sigma-Aldrich, St Louis, MO)
or vehicle for 10 hours. At the end of the experiments or
at 0, 48, or 72 hours for the CDE diet, mice were sacri-
ficed by cervical dislocation. Blood was sampled, and
sera were stored at 20°C until assays (hydrolase mea-
surements in both models; assessment of plasmatic lev-
els of tryptase, IL-33, and IL-6 in the CDE model). Pan-
creatic glands were excised and fixed in formaldehyde
for histological assessment.
Assessment of Severity of Experimental Acute
Pancreatitis
Paraffin-embedded pancreatic sections were stained
with H&E and examined in a blinded manner by two
independent investigators (R.O. and P.D.) The severity of
AP was graded by a semiquantitative assessment of
edema, inflammatory cell infiltrate, acinar necrosis, and
vacuolization. The scoring system used in the cerulein
model (Table 2) is adapted from Moreno et al.18 In the
CDE diet model, the grading refers to a five-point scale
ranging from 0 (absent) and 1 (minimal) to 4 (maximal).
Table 1. Characteristics of Patients with Acute Pancreatitis
Characteristic Value
Sample size n  44
Age (years) 54 (17–86)
Sex, male/female (%) 43/57
BMI (kg·m2) 26.8 (18.6–59)
Etiology [no. (%)]
Biliary 27 (61)
Ethanol 9 (21)
Other 8 (18)
Time of inclusion after onset of
symptoms (hours)
16 (6–24)
Time from onset of symptoms to
CT/MRI (hours)
15 (2–120)
Necrotizing/interstitial AP (%) 20/80
CTSI or MRSI 3 (0–10)
Necrosis
None 33
30% 4
30% to 50% 1
50% 2
Not available 4
MOF [no. (%)] 1 (2)
SIRS [no. (%)] 22 (50)
Ranson’s score* at 48 hours 2 (0–7)
CRP at admission (mg/dL) 1.2 (0–24)
CRP at 24 hours (mg/dL) 13.5 (0.1–35)
ICU admission [no. (%)] 8 (18)
Length of hospitalization (days) 7 (3–65)
Death [no. (%)] 1 (2)
Classification,† mild/severe [no. (%)] 17/27 (38.6/61.4)
Data are presented as the median (range) or percent of total.
*On a scale of 0 to 11.
†Severity of acute pancreatitis according to the Atlanta classification.16
BMI, body mass index; CRP, C-reactive protein; CT, computed tomog-
raphy; CTSI, CT severity index; ICU, intensive care unit; MOF, multiple
organ failure; MRI, magnetic resonance imaging; MRSI, MRI severity
index; SIRS, systemic inflammatory response syndrome.For necrosis and intracellular vacuolization, this grading
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0  absent; 1  5% to 15%; 2  15% to 35%; 3  35%
to 50%; and 4  50%.19 Severity items were calculated
as mean score value/10 pancreatic fields at 200 mag-
nification.
Amylase and lipase levels were quantified using au-
tomated chromogenic assays with commercially avail-
able kits (Roche/Hitachi, Roche Diagnostics, Mann-
heim, Germany).
Immunoassays
Sensitivity of the enzyme-linked immunosorbent assay
(ELISA) used to quantify human sST2 and mouse IL-6,
IL-33, and IL-13 (DuoSet or Quantikine; R&D Systems,
Minneapolis, MN) was 15.6, 7.8, 31.3, and 7.8 pg/mL
respectively.
Immunohistochemistry and Mast Cell Staining
Formalin-fixed, paraffin-embedded pancreas tissue sam-
ple sections (5 m thick) were deparaffinized in xylene.
Epitope retrieval was achieved by boiling the sections in
EDTA buffer (pH 9) in a microwave oven (600 W; 2  5
minutes with 5 minutes rest between the two). Endoge-
nous peroxidases were quenched with 30% H2O2
(Merck, Darmstadt, Germany) in methyl alcohol for 30
minutes. Nonspecific background staining was inhibited
by 10 minutes incubation with 5% horse serum (Vector
Laboratories, Burlingame, CA). Avidin-biotin blocking re-
agents were used for 30 minutes to block endogenous
biotin. Sections were incubated for 1 hour at room tem-
perature with polyclonal goat anti-human IL-33 antibody
Table 2. Histological Scoring System Used to Assess the
Severity of Acute Pancreatitis Induced by Cerulein
Injection
Scoring Indication
Edema
0 Absent
1 Focally increased between
lobules
2 Diffusely increased between
lobules
3 Acini disrupted and separated
Inflammatory cell
infiltrate
0 Absent
1 Rare or around ductal margins
2 In the parenchyma (50% of
the lobules)
3 In the parenchyma (50% of
the lobules)
Necrosis
0 Absent
1 Architectural changes, pycnotic
nuclei
2 Focal necrosis (10% of the
parenchyma)
3 Diffuse parenchymal necrosis
(10% of the parenchyma)
Adapted from the scoring system of Moreno et al.18(5 g/mL) (AF3626; R&D systems, Abingdon, UK). There-after, sections were incubated with biotin-conjugated
secondary antibody (anti-goat IgG, 1:200; Vector Labo-
ratories). Immunoreactivity was visualized by avidin-
biotin-peroxidase complex (ABC) kit reagents (Vector
Laboratories) and 3,3=-diaminobenzidine (BioGenex, Fre-
mont, CA) in 50 mmol/L Tris-buffer (pH 7.6) containing
0.3% H2O2. Finally, sections were weakly counterstained
with hematoxylin. Normal goat IgG was used as a nega-
tive control.
Toluidine blue staining was used to identify mast
cells.20 Consecutive pancreas tissue samples were
deparaffinized in xylene and stained with a solution con-
taining 0.1% toluidine blue (Sigma-Aldrich), 4% formal-
dehyde, and 1% acetic acid (pH 2.8) for 20 minutes. After
a washing, slides were incubated in ethanol 95% until
mast cells appeared deep red.
RNA Extraction and RT-PCR
Total RNA was extracted from freshly lysed pancreas
using a commercially available kit (TriPure; Roche Di-
agnostics, Basel, Switzerland) according to the manu-
facturer’s instructions. Preparation of cDNA and PCR
for ST2, IL33, and hypoxanthine-guanine phosphoribo-
syltransferase (HPRT) genes were performed using
standard procedures. Reactions were incubated in a
DNA thermal cycler for 33 cycles for ST2 and IL33 (de-
naturation, 20 seconds at 94°C; annealing, 20 seconds at
58°C; extension, 30 seconds at 72°C). Thereafter, PCR
products were loaded onto a FlashGel system (Lonza,
Rockland, ME). Sense and antisense PCR primer se-
quences were as follows: HPRT, 5=-ATGGACAGGACT-
GAAAGA-3= and 5=-AATGACACAAACGTGATTC-3=; ST2,
5=-GGTGAAGCAAGAATTCAAGAAG-3= and 5=-CAGG-
Figure 1. sST2 levels in humans. Plasma sST2 levels measured in patients
(n  44) admitted within 24 hours of onset of AP symptoms, compared with
healthy subjects (HS) (n  16). Blood sample puncture was performed at
†days 0, 1, 2, 7, and 30. P  0.01 versus HS; *P  0.05; **P  0.01 AP day 30
versus other AP blood sample times.
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CAAGCATGAAGAGA-3= and 5=-TGCATTCAAATGAAA-
CAAAGTC-3=.
Peritoneal Cell Cytologic Analysis
Six WT and five Il1rl1/ mice were injected with 10 mL
i.p. of saline solution, and the cell suspension was col-
lected for flow cytometry analysis of ST2 membranous
expression. In addition, 2  105 cells were centrifuged
onto a glass slide for toluidine blue staining and confir-
mation of the presence of mast cells as deep red cells
under light microscopy. Surface staining was performed
using fluorescein-isothiocyanate-labeled anti-ST2 (clone
DJ8), allophycocyanin-labeled anti-c-kit (clone 2B8),
anti-CD4 (clone RM4-5), anti-CD11b (clone M1/70), and
phycoerythrin-labeled anti-FcRI (clone MAR-1), anti-
CD3 (clone 145-2C11), anti-Ly6G (clone 1A8), and anti-
F4/80 (clone BM8). Fluorochrome-conjugated antibodies
were purchased from MD Biosciences (Zürich, Switzer-land), eBioscience (Vienna, Austria), or BD Biosciences
(Erembodegem, Belgium). Cell acquisition was per-
formed using a FACSCalibur flow cytometry system, and
analyses were done with CellQuest Pro software 4.0 (BD
Biosciences).
Bone-Marrow-Derived Mast Cells
Bone-marrow-derived mast cells (BMMCs) were isolated
according to a previously published protocol.21 Briefly,
BMMCs were obtained by culturing femoral bone marrow
cells from WT and Il1rl1/ mice in Iscove’s modified
Dulbecco’s medium (Lonza) containing 10% FBS, 100
IU/mL penicillin, 100 g/mL streptomycin, 250 ng/mL
amphotericin B (Gibco; Life Technologies, Paisley, UK),
and 5  105 mol/L -mercaptoethanol. Nonadherent
cells were cultured for 6 to 12 weeks in the presence of
IL-3 (5 ng/mL) and stem cell factor (SCF) (50 ng/mL;
Invitrogen-Life Technologies, Paisley, UK). Thereafter,
cell purity was controlled by flow cytometry, revealing
Figure 2. CDE diet model in WT mice and ST2-
deficient Il1rl1/ mice (ST2/). Serum amy-
lase (A) and lipase (B) levels were measured in
mice exposed to the CDE diet for 0, 48, and 72
hours. Data are presented as means  SEM of
pooled data of 10 (baseline) to 24 (CDE group)
mice per group from seven independent exper-
iments. C: H&E staining for histological assess-
ment of the pancreas after 72 hours of CDE diet
in WT and Il1rl1/ mice. Original magnifica-
tion, 200. D: Semiquantification of histological
severity of pancreatitis in WT (n  24) and
Il1rl1/ (n  15) mice fed a CDE diet for 72
hours. E, edema; I, inflammation; N, necrosis; V,
vacuolization. Data are presented as pooled
scores from five independent experiments. E:
IL-6 levels assessed by ELISA in serum of WT and
Il1rl1/ mice during CDE diet-induced AP.
Data are presented as means  SEM of pooled
data of 15 (baseline) to 33 (CDE group) mice per
group from nine independent experiments.
*P  0.05 versus baseline; †P  0.01 WT versus
Il1rl1/ at 72 hours (A and B). *P  0.05 WT
versus Il1rl1/; **P  0.01 WT versus
Il1rl1/ (D). †P  0.001 WT versus Il1rl1/
at 72 hours (E).
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tiated mast cells. For in vitro experiments, 106 BMMCs/
well were cultured for 24 hours with lipopolysaccharide
(LPS) (1 g/mL; E. coli serotype 055:B5; Sigma-Aldrich)
or with mouse rIL-33 (10 ng/mL; R&D Systems, Minneap-
olis, MN). Tryptase activity in BMMC culture supernatants
and in mouse sera was assayed with a mast cell degran-
ulation assay kit (Merck Millipore, Darmstadt, Germany)
according to the manufacturer’s protocol, in which cal-
cium ionophore was used as an inducer of degranulation
and protamine as an inhibitor of it.
Pancreas Cell Preparation
Acinar cells were isolated as described previously,22 with
slight modifications. In overnight-fasted WT mice not re-
ceiving any treatment, pancreata were dissected free of
mesenteric fat, minced in Hank’s buffered saline solution
with 5 mmol/L EDTA solution at 37°C, and centrifuged for
2 minutes at 500  g twice to eliminate fat. The tissues
were rinsed in Waymouth’s medium (Invitrogen-Life
Technologies) containing penicillin and streptomycin (0.1
mg/mL; Lonza), 20% FBS, and 0.01% soybean trypsin
inhibitor (Sigma-Aldrich) and were digested by means of
two cycles of shaking at 25 cycles/minute in a solution of
6.25 U/mL collagenase in Hank’s buffered saline solution
containing 0.2% bovine serum albumin at 37°C. Nondi-
gested tissue was eliminated by 70-m pore filtration,
and isolated cells were washed twice in complete Way-
mouth’s medium. Thereafter, acinar cells were isolated
on 60%/20% Ficoll gradient centrifugation and washed
twice in Ham’s F-12K (Kaighn’s) medium (Invitrogen-Life
Technologies) containing 10% FCS, 0.5% bovine serum
albumin, 0.01% soybean trypsin inhibitor, and 0.1 mg/mL
penicillin and streptomycin, leading to an acinar cell sus-pension of small aggregates. Acinar cells (5  106 cells/
mL) from WT mice were sonicated, and IL-33 was mea-
sured by ELISA in the lysed cell suspension.
Statistical Analysis
Data are expressed as median and range (minimum to
maximum). Multiple comparisons were performed with
the Kruskal-Wallis test. The Mann-Whitney U-test was
used for post hoc analysis. Nonparametric correlations
were calculated with the Spearman’s test; comparisons
between paired data were calculated with the Wilcoxon
test. Calculations were performed with SPSS 15.0 soft-
ware (IBM SPSS, Chicago, IL). The level of statistical
significance was set at P  0.05.
Results
In Humans, sST2 Levels Increase Early during
AP and Correlate with AP Severity
On the day of admission (day 0), sST2 levels were dra-
matically increased in the plasma of patients with AP
(2924 pg/mL; range, 87 to 2  106), compared with
healthy subjects (56.5 pg/mL; range, 0 to 546; P 
0.001). These levels remained elevated during the early
AP period and decreased to near-normal ranges 30 days
after the acute episode in patients (119 pg/mL; range, 0
to 1267; P  0.06 versus healthy subjects) (Figure 1).
On the first day after admission (day 1), plasma sST2
levels were higher in patients who developed necrotizing
pancreatitis than in those with edematous AP [5584 pg/mL
(range, 215 to 2  106) versus 1147 pg/mL (range, 15 to
2  106); P  0.05]. Furthermore, sST2 plasma levels on
day 1 correlated significantly with the need for intensive
Figure 3. Cerulein model. Serum amylase (A) and
lipase (B) levelsmeasured inWT (and Il1rl1/mice
exposed to 10 hourly cerulein or vehicle (Veh) injec-
tions. Data are presented as means SEM of pooled
data of 4 (vehicle) to 30 (cerulein) mice per group
from three independent experiments. *P 0.01 ver-
sus vehicle. †P  0.01 WT versus Il1rl1/ after ce-
rulein. C:H&E staining for histological assessment of
the pancreas after cerulein inWT and Il1rl1/mice.
Original magnification, 200. D: Semiquantification
of histological severity of pancreatitis inWT (n 30)
and Il1rl1/ (n 30) mice exposed to cerulein. E,
edema; I, inflammation; N, necrosis. Data are pre-
sented as means SEM of pooled values from three
independent experiments. *P  0.01 WT versus
Il1rl1/.
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ence of severe AP ( 0.316, 0.313, and 0.358, respectively).
ST2-Deficient Mice Present More Severe AP
Given that we had demonstrated activation of the ST2
pathway in humans during AP, and to gain further insight
into its possible role in AP, we submitted WT and Il1rl1/
mice to two experimental models of AP. Severity of AP
was evaluated both in the CDE diet-induced AP model
(Figure 2) and in the cerulein model (Figure 3).
After 72 hours of a CDE diet, Il1rl1/ mice had signif-
icantly higher levels of hydrolases than WT mice [amy-
lase, 19,620 IU/L (range, 7272 to 55,132) versus 7740
IU/L (range, 1300 to 19,492) (P  0.001); lipase, 1180
IU/L (range, 280 to 4884) versus 128 IU/L (range, 32 to
1352) (P  0.001)] (Figure 2, A and B). Pancreatic histo-
logical assessment revealed more severe necrosis, in-
flammation, and edema in Il1rl1/ mice than in WT mice
(Figure 2, C and D). In addition, 72 hours after the CDE
diet, IL-6 concentrations were significantly higher in sera
of Il1rl1/ mice than in WT mice (Figure 2E).
In line with these results, Il1rl1/ mice also presented
more severe disease after 10 hourly cerulein injections.
Their hydrolase levels were significantly higher than
those of WT mice [amylase, 17,424 IU/L (range, 6336 to
49,196) versus 8856 IU/L (range, 4080 to 36860) (P 
0.01); lipase, 626 IU/L (range, 128 to 3260) versus 186 IU/L
(range, 64 to 2260) (P 0.01)] (Figure 3, A and B). Il1rl1/
mice presented higher edema, inflammation, and necrosis
histological scores than WT mice (Figure 3, C and D).Peritoneal Mast Cells Express ST2
In normal murine pancreas, expression of ST2 mRNA was
at the limit of detection, compared with clear expression
of its ligand IL-33 (Figure 4A). We therefore looked out-
side the pancreas for the presence of the ST2 receptor.
Peritoneal cells were obtained by peritoneal lavage of WT
and Il1rl1/ mice and assessed for ST2 expression by
flow cytometry. We looked for ST2 expression on WT
peritoneal cells using Il1rl1/ cellular suspension as
negative control. We observed that 1.9% (range, 1.1% to
2.2%) of all peritoneal cells were ST2. Furthermore,
gating on this ST2 cell population, we could not detect
any CD11b F4/80 Ly6G neutrophils, nor any CD11b
F4/80 Ly6G macrophages. However, a small minority
(1.8%; range, 1.7% to 1.8%) was CD3CD4 (T lympho-
cytes) but a large majority (98.0%; range, 97.4% to
98.4%) was c-kit FcRI (mast cells) (Figure 4B).
Mast Cells Are Activated during AP, and Their
ST2 Receptor Is Involved in the Degranulation
Process
With toluidine blue staining, we confirmed the presence
of a few mast cells in pancreatic interlobular spaces at
baseline and their increase in peripancreatic peritoneal
tissue during the course of CDE diet-induced AP (Figure
5A). To assess mast cell activation during experimental
AP, we measured the tryptase concentration in sera of
Figure 4. ST2 and IL-33 mRNA expression. A:
HPRT (housekeeping gene), ST2, and IL-33
mRNA constitutive pancreatic expression was
detected by classical RT-PCR on freshly isolated
WT and Il1rl1/ pancreas. Each analysis was
performed in duplicate. B: Flow cytometry anal-
ysis of peritoneal cells isolated from mice focus-
ing on c-kit FceRI cells (mast cells) (left
panel) shows their ST2 expression in WT mice
but not in the negative control Il1rl1/ mice
(right panel). FITC, fluorescein isothiocyanate;
PE, phycoerythrin; APC, allophycocyanin.mice submitted to the CDE diet model.23 Tryptase levels
riments
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significantly greater in Il1rl1/mice (Figure 5B), confirm-
ing mast cell activation in AP.
Given that mast cell activation is higher in Il1rl1/
mice, we studied their degranulation potential by mea-
suring tryptase in the supernatants of BMMCs generated
from WT and Il1rl1/ mice. Flow cytometry analysis of
isolated BMMCs confirmed their mast cell phenotype (c-
kit FcRI) and the absence of ST2 expression on
BMMCs isolated from Il1rl1/ mice (Figure 5C). Degran-
ulation was induced by calcium ionophore and was inhib-
ited by protamine (used as a negative internal control). After
stimulation, Il1rl1/ mast cells exhibited higher tryptase
concentrations in supernatants, compared with WT cells
[96.8 g/mL (range, 44.9 to 145.6) versus 15.1 (range, 4.1
to 29.3); P 0.05] (Figure 5D), confirming ST2 involvement
in the mast cell degranulation process.
In Mice, IL-33, the ST2 Ligand, Is Expressed in
the Pancreas at Baseline and Is Released
during AP
Both WT and Il1rl1/ pancreas exhibited constitutive
IL-33 mRNA expression (Figure 4A) without any quanti-
tative difference. Immunohistochemistry confirmed con-
Figure 5. Mast cell involvement in pancreatitis. A: Toluidine blue stainin
(arrows) in interlobular septa (left) and peripancreatic tissue (right). Or
mice at baseline and after 72 hours of CDE diet. Data are presented as mea
from three independent experiments. C: BMMCs expressing c-kit and Fc
cells is indicated in each quadrant (left). FITC, fluorescein isothiocyanate
the supernatants of BMMCs. Degranulation was either stimulated (S) by c
are presented as mean  SEM of pooled data from four independent expe
WT versus Il1rl1/ BMMCs (D).stitutive pancreatic IL-33 expression localized in the cy-toplasm of acinar cells (Figure 6A). Furthermore, after isolation
and sonication of 5 106 acinar cells/mL, wemeasured IL-33
in the lysed cell suspension by ELISA at 37 pg/mL, confirming
acinar cell IL-33 production at the protein level.
After 48 and 72 hours of the CDE diet leading to AP in
mice, IL-33 concentrations rose significantly in the serum
[control diet, 43.3 pg/mL (range, 0 to 169.2); 48-hour
CDE diet, 128.6 pg/mL (range, 53.1 to 397.3); 72-hour
CDE diet, 427 pg/mL (range, 18 to 1707); P  0.001
versus control] (Figure 6B).
Recent reports suggest a regulatory role for IL-33 in
the mast cell degranulation process.24,25 In the present in
vitro experiments, however, we could not observe this
effect, because incubation of BMMCs with IL-33 did not
modify tryptase levels detected in supernatants either in
Il1rl1/ BMMCs or in WT BMMCs (data not shown).
Nevertheless, because degranulation and production of
proinflammatory cytokines by stimulated BMMCs are two
independent processes,9,26 we confirmed their normal
activity by using LPS or IL-33 as stimulators and positive
controls. In agreement with previous findings,26 LPS did
induce IL-6 and IL-13 secretion by mast cells indepen-
dently of ST2. Moreover, as Moulin et al27 reported, IL-33
alone was able to induce proinflammatory cytokine pro-
duction by WT BMMCs, but not by Il1rl1/ BMMCs (Fig-
T mouse pancreas exposed to 72 hours of CDE diet indicates mast cells
agnification, 200. B: Tryptase concentration in sera of WT and Il1rl1/
M of pooled data of 5 (baseline) to 12 (72 hours CDE diet) mice per group
t) from WT and Il1rl1/ mice were isolated (right). The percentage of
ycoerythrin; APC, allophycocyanin. D: Tryptase activity was measured in
ionophore (10 nmol/L) or inhibited (I) by protamine (100 nmol/L). Data
. *P  0.01 versus baseline; †P  0.05 WT versus Il1rl1/ (B). *P  0.05g of W
iginal m
n  SE
eRI (lef
; PE, ph
alciumure 6, C and D).
perimen
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The present study reports for the first time the involvement of
the ST2 receptor in the severity of acute pancreatitis. The
ST2 pathway is activated early in the course of AP in hu-
mans and correlates with severity of the disease. Further-
more, ST2-deficient mice developed more severe pancre-
atitis in two independent experimental models, suggesting
a protective role of the pathway during AP. In addition, we
showed that mast cells express ST2 and that the receptor
seems to be involved in their degranulation process. Finally,
we showed that IL-33, the ST2 ligand, is expressed by
pancreatic acinar cells and is released during AP.
High levels of sST2 are described in several human
illnesses.28–31 Soluble ST2 is a powerful predictor of mor-
tality in heart failure32 and myocardial infarction,33 and is
proposed as a novel biomarker in cardiovascular dis-
eases.34 Although the biological function of elevated
sST2 in patients with AP is still uncertain, our in vivo
murine data suggest a protective pathogenic role for ST2,
rather than simply that of a biomarker.
ST2 exists in two isoforms35 and both can exert pro-
tective functions. The use of sST2-Fc fusion protein pro-
tects mice in several inflammatory experimental models,
suggesting an anti-inflammatory role for sST2 as a decoy
receptor binding IL-33.36,37 On the other hand, Brint
et al14 identified the transmembrane form as a negative
regulatory component of IL-1RI/TLR4 signaling, inhibiting
LPS-induced production of proinflammatory cytokines. In
Figure 6. Pancreatic and plasma expression of IL-33. A: Immunohistochemical ex
immunostaining reveals acinar cell IL-33 expression. Original magnification,200.
and D: Inflammatory activity of BMMCs isolated from WT and Il1rl1/ mice was
BMMCs nonstimulated (NS) or stimulated by LPS or rIL-33. Data are presented as m
nine mice per group (B), or of duplicate data representative of three independent ex
of CDE diet.the present study, we also observed a protective role forST2 in AP: ST2-deficient mice exhibited more severe
disease than WT in two different experimental models.
Pancreatic expression of TNF-, IL-1, IL-6, and IL-13
did not differ between WT and Il1rl1/mice in the course
of AP (data not shown). In addition to hydrolase measure-
ments, pancreatic histological scoring, and serum IL-6
levels indicating greater severity of pancreatitis in
Il1rl1/mice, we also observed elevated serum concen-
trations of tryptase in these knockout mice. Given that
tryptase is a reflection of mast cell activation,23 and that
these cells are known to be involved in the physiopathol-
ogy of pancreatitis,38 it seems unlikely that these levels
are simply another marker of severity; rather, they prob-
ably indicate activation of mast cells during our experi-
mental model of AP, and even more in Il1rl1/ mice.
Moreover, mast cells are known to express ST2.39,40 In
the present study, we not only identified the peripancre-
atic location of mast cells, but also showed that they were
the main cell population in the peritoneal cavity to ex-
press ST2.
Mast cell degranulation, associated with tryptase
release, is an early event in AP in humans and in rodent
models.41,42 Several reports have suggested a regula-
tory role for IL-33, the ST2 ligand, in this process.27,39
In the present work, however, and in accord with re-
ports of others,9,43,44 we were unable to demonstrate
this regulatory role, although BMMCs were normally
responsive to IL-33 in terms of cytokine production.
of IL-33 in the pancreas of control WTmice. IL-33 (left) and control isotype (right)
quantification of serum IL-33 levels after the indicated time of CDE diet in mice. C
d by ELISA quantification of IL-6 (C) and IL-13 (D) production in supernatants of
EM of pooled values of seven independent experiments, each comprising three to
ts (C andD). **P 0.001 versus control group. †P 0.05 48 hours versus 72 hourspression
B: ELISA
evaluate
ean SNonetheless, the constitutive presence or absence of
2338 Ouziel et al
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tion, because we demonstrated that Il1rl1/ BMMCs
degranulate more than WT BMMCs. In addition, these
data were consistent with our in vivo experiments, in
which the tryptase concentration increased in sera of
mice during CDE-induced AP, and significantly more in
Il1rl1/ mice. We therefore speculate that ST2 plays a
key role in regulation of the severity of pancreatitis.
IL-33 has been reported to be expressed mainly by
endothelial cells, fibroblasts, adipocytes, synovium,45
and, more recently and specifically, by pancreatic
myofibroblasts46 and cardiac fibroblasts.13 In the pres-
ent study, we showed that pancreatic acinar cells con-
stitutively express IL-33 mRNA and protein, and that
AP is associated with an increase in the serum con-
centration of IL-33 in mice. In humans, however, IL-33
was detectable in only 9 of the 44 patients and did not
correlate with AP severity (data not shown). Functions
and secretion mechanisms of this newly identified cy-
tokine10 are not yet fully elucidated. In asthma, arthritis,
and anaphylactic shock, exogenous IL-33 was shown to
exacerbate the disease through ST2 activation.24,47,48 In
contrast, activation of ST2 leading to sequestration of
MyD8814 or inhibition of cardiomyocyte hypertrophy13 sug-
gests a protective role for IL-33. It has been described as a
double agent, acting in the nucleus as an inhibitor of NF-
B-dependent gene expression6,7 or in a paracrine manner
as an alarmin.8,9
Given that IL-33 is constitutively expressed in the
pancreas and that its levels increase in serum during
AP, our results suggest that IL-33 is implicated in AP
and is more likely to act as an endogenous danger
signal, like high mobility group protein B1 (HMGB1).49
Enoksson et al9 recently identified mast cells as impor-
tant contributors to early cell injury responses and
acute inflammation. They confirmed the central role
played by IL-33 released by necrotizing cells in mast
cell proinflammatory activation. Moreover, two recent
reports strongly implicate IL-33 involvement in human
chronic pancreatitis. One study showed that pancre-
atic stellate cells express IL-33 and ST2,50 and the
other reported the expression of these molecules by
pancreatic myofibroblasts.46 Because we demon-
strated that the ST2 pathway is protective in the acute
phase of pancreatitis, we speculate that, as the dis-
ease evolves to a chronic form, this pathway might
become noxious by promoting fibrosis,51 but this will
require confirmation in vivo.
In conclusion, we have demonstrated for the first time
the involvement of the IL-33-ST2 pathway in the patho-
physiology of AP in humans, with a rise in sST2 levels in
human serum during AP and its correlation with disease
severity. In mice, we show that ST2 plays a protective role
in AP and is expressed by peritoneal mast cells, which
are activated during AP. Finally, we demonstrate that
IL-33, the ST2 ligand, is expressed by murine pancreatic
acinar cells and is released during AP. Thus, the IL-33–
ST2 pathway might constitute a new therapeutic target for
modulating immune activation during the AP inflamma-
tory storm.Acknowledgment
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